EU Decision Thwarts Novartis's Near-Term Piqray Ambitions
Company Has Pulled Its UK HTA Submission
Novartis seems to have accepted the fact that the indication granted for Piqray in the EU means there is little scope for the advanced breast cancer drug to be used in markets such as the UK.
